🔗 Visit the ClinicalTrials.gov page for NCT03190941
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Cancer regression in patients after transfer of genetically engineered lymphocytes. | Science | 2006 | 16.96 |
| 2 | Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. | J Clin Oncol | 2008 | 10.13 |
| 3 | Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. | J Clin Oncol | 2011 | 9.19 |
| 4 | Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. | Clin Cancer Res | 2010 | 1.44 |
| 5 | Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. | Cancer Immunol Res | 2015 | 0.94 |
| 6 | Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. | Cell Immunol | 1997 | 0.89 |